Pervej Alom Barbhuiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Pervej Alom Barbhuiya has a total of 63 co-authors. Here are the top co-authors by number of shared publications:
- Manash Pratim Pathak
Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, India
18 shared publications - Saikat Sen
Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, India
7 shared publications - Punam Kumari
Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, India
6 shared publications Manash Pratim Pathak
Assam down town University
4 shared publications- Ameena Ahmed
Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, India
3 shared publications - Binita Chakraborty
Faculty of Pharmaceutical Science, Assam down town University, Panikhaiti, Guwahati, India
2 shared publications
Latest Publications
- 20 August 2026
- Published by Springer Nature in Journal of Packaging Technology and Research
- Vol. 10 (2-3) , 111-138
Citrus Essential Oils in Sustainable Food Preservation and Active Packaging: Current Advances, Challenges and Future Perspectives
- 20 August 2026
- Published by Springer Nature in Journal of Packaging Technology and Research
- Vol. 10 (2-3) , 111-138
Citrus Essential Oils in Sustainable Food Preservation and Active Packaging: Current Advances, Challenges and Future Perspectives
- 14 August 2026
- Published by Springer Nature in Current Nutrition Reports
- Vol. 15 (1) , 68
Mechanistic Insights into Houttuynia cordata Thunb. as a Potential Therapeutic Strategy Targeting Metabolic Disorders in Preclinical Models
- 14 August 2026
- Published by Springer Nature in Current Nutrition Reports
- Vol. 15 (1) , 68
Mechanistic Insights into Houttuynia cordata Thunb. as a Potential Therapeutic Strategy Targeting Metabolic Disorders in Preclinical Models
- 17 July 2026
- Published by Springer Nature in Current Hepatology Reports
- Vol. 25 (1)
Epitranscriptomic Remodeling: m6A Methylation as a Master Regulator of de novo Lipogenesis in MASLD
- 17 July 2026
- Published by Springer Nature in Current Hepatology Reports
- Vol. 25 (1)
Epitranscriptomic Remodeling: m6A Methylation as a Master Regulator of de novo Lipogenesis in MASLD
- 17 March 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1) , 22
MASLD In Children - A Distinct Phenotype?
- 17 March 2026
- Published by Springer Nature in Current Obesity Reports
- Vol. 15 (1) , 22
MASLD In Children - A Distinct Phenotype?
- Open Access
- 3 March 2026
- Published by Wiley
Epitranscriptomic Remodeling: m6A Methylation as a Master Regulator of De Novo Lipogenesis in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is rapidly being recognized as a world health crisis, touching nearly a third of the world’s population. A key step in the progression of MASLD from simple steatosis to full-blown fibrosis is the unregulated lipid metabolism of the liver, especially the overexpression of de novo lipogenesis (DNL). Researchers have identified RNA methylation in the form of N-6 Methyladenosine (m6A) as the master regulator of this unregulated lipid metabolism. It incorporates different regulators, termed writers, erasers, and readers, which determine the fate of lipid metabolism regulator transcripts. In MASLD, these regulators have been found to be compromised, especially in instances where the regulators expression are altered which results in the stabilization of lipid regulators such as SREBP-1c, FASN etc. However, of specific interest is the fact that m6A regulators are connected not only to lipid synthesis but also integrate signals of insulin resistance, oxidative stress, and mitochondrial dysfunction. This article aims to explore the relationship between m6A remodeling pathways and DNL in MASLD pathogenesis. It also addresses the therapeutic implications including both synthetic and natural products of these regulators towards managing MASLD by means of epitranscriptomic profiling.
- 3 March 2026
- Published by Wiley
Open AccessEpitranscriptomic Remodeling: m6A Methylation as a Master Regulator of De Novo Lipogenesis in MASLD
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) is rapidly being recognized as a world health crisis, touching nearly a third of the world’s population. A key step in the progression of MASLD from simple steatosis to full-blown fibrosis is the unregulated lipid metabolism of the liver, especially the overexpression of de novo lipogenesis (DNL). Researchers have identified RNA methylation in the form of N-6 Methyladenosine (m6A) as the master regulator of this unregulated lipid metabolism. It incorporates different regulators, termed writers, erasers, and readers, which determine the fate of lipid metabolism regulator transcripts. In MASLD, these regulators have been found to be compromised, especially in instances where the regulators expression are altered which results in the stabilization of lipid regulators such as SREBP-1c, FASN etc. However, of specific interest is the fact that m6A regulators are connected not only to lipid synthesis but also integrate signals of insulin resistance, oxidative stress, and mitochondrial dysfunction. This article aims to explore the relationship between m6A remodeling pathways and DNL in MASLD pathogenesis. It also addresses the therapeutic implications including both synthetic and natural products of these regulators towards managing MASLD by means of epitranscriptomic profiling.
- Top Cited Papers
- 2 February 2026
- Published by Taylor & Francis in Journal of Essential Oil Research
- Vol. 38 (2) , 133-159
Advanced encapsulation techniques for essential oils: enhancing stability and bioavailability through nanocarriers
- 2 February 2026
- Published by Taylor & Francis in Journal of Essential Oil Research
- Vol. 38 (2) , 133-159
Top Cited PapersAdvanced encapsulation techniques for essential oils: enhancing stability and bioavailability through nanocarriers
- 3 January 2026
- Published by Springer Nature in Current Nutrition Reports
- Vol. 15 (1) , 1
Bioactive Phytoconstituents Targeting Energy Expenditure and Appetite to Combat Obesity: A Comprehensive Review
Purpose of Review Obesity has emerged as a worldwide health issue because of sedentary lifestyles, inadequate nutritional practices, and metabolic dysfunction. Traditional anti-obesity medications, although efficacious, often exhibit considerable adverse effects, resulting in their market removal. Consequently, there is increasing interest in natural phytoconstituents that may regulate obesity by influencing appetite, satiety, and energy expenditure via thermogenesis. This review emphasizes on various bioactive phytoconstituents that ameliorate obesity by modulating energy expenditure and appetite while also putting the focus on various reported mechanisms of the determined effect. Recent Findings Appetite and satiety are regulated by hypothalamic neurons (AgRP/NPY and POMC) and gastrointestinal hormones (ghrelin, CCK, GLP-1, PYY), with phytoconstituents such as celastrol, protopanaxadiol, hydroxycitric acid, naringenin, and β-sitosterol successfully inhibiting appetite via these mechanisms. Furthermore, thermogenic agents like capsaicin, gingerols, curcumin, caffeine, fucoxanthin, and resveratrol increase energy expenditure by stimulating brown adipose tissue (BAT), upregulating uncoupling protein 1 (UCP-1), and facilitating lipolysis. Certain phytoconstituents, such as β-caryophyllene and guggulsterone, demonstrate dual actions by suppressing hunger and enhancing thermogenesis. In comparison to traditional anti-obesity medications (e.g., phentermine, sibutramine, GLP-1 agonists), these natural alternatives have similar effectiveness with less side effects, establishing them as viable therapeutic choices for obesity treatment. Summary This study emphasizes the efficacy of phytoconstituents in obesity management via hunger suppression and thermogenic stimulation. These natural substances provide a safer and more effective method for weight control by focusing on neuroendocrine signaling, mitochondrial uncoupling, and adipokine modulation. Future research must concentrate on clinical validation, increase of bioavailability, and synergistic combinations to maximize anti-obesity benefits.
- 3 January 2026
- Published by Springer Nature in Current Nutrition Reports
- Vol. 15 (1) , 1
Bioactive Phytoconstituents Targeting Energy Expenditure and Appetite to Combat Obesity: A Comprehensive Review
Purpose of Review Obesity has emerged as a worldwide health issue because of sedentary lifestyles, inadequate nutritional practices, and metabolic dysfunction. Traditional anti-obesity medications, although efficacious, often exhibit considerable adverse effects, resulting in their market removal. Consequently, there is increasing interest in natural phytoconstituents that may regulate obesity by influencing appetite, satiety, and energy expenditure via thermogenesis. This review emphasizes on various bioactive phytoconstituents that ameliorate obesity by modulating energy expenditure and appetite while also putting the focus on various reported mechanisms of the determined effect. Recent Findings Appetite and satiety are regulated by hypothalamic neurons (AgRP/NPY and POMC) and gastrointestinal hormones (ghrelin, CCK, GLP-1, PYY), with phytoconstituents such as celastrol, protopanaxadiol, hydroxycitric acid, naringenin, and β-sitosterol successfully inhibiting appetite via these mechanisms. Furthermore, thermogenic agents like capsaicin, gingerols, curcumin, caffeine, fucoxanthin, and resveratrol increase energy expenditure by stimulating brown adipose tissue (BAT), upregulating uncoupling protein 1 (UCP-1), and facilitating lipolysis. Certain phytoconstituents, such as β-caryophyllene and guggulsterone, demonstrate dual actions by suppressing hunger and enhancing thermogenesis. In comparison to traditional anti-obesity medications (e.g., phentermine, sibutramine, GLP-1 agonists), these natural alternatives have similar effectiveness with less side effects, establishing them as viable therapeutic choices for obesity treatment. Summary This study emphasizes the efficacy of phytoconstituents in obesity management via hunger suppression and thermogenic stimulation. These natural substances provide a safer and more effective method for weight control by focusing on neuroendocrine signaling, mitochondrial uncoupling, and adipokine modulation. Future research must concentrate on clinical validation, increase of bioavailability, and synergistic combinations to maximize anti-obesity benefits.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 25 (27) , 3190-3202
Therapeutic Potential of Genistein: Insights into Multifaceted Mechanisms and Perspectives for Human Wellness
Background: Genistein, a natural isoflavonoid found predominantly in legumes and soy-based foods, has garnered significant attention due to its multifaceted mechanisms and potential therapeutic applications. Chemically, genistein is a 4',5,7-Trihydroxyisoflavone having a molecular formula of C15H10O5, which enables its interactions with diverse biological targets. Objective: The main objective of this review is to summarize the pharmacological effects of genistein, elucidating its potential mechanisms of action. Furthermore, the review emphasizes genistein's impact on human health when used as a dietary supplement. Methods: The authors have gone through a vast number of article sources from various scientific databases like Google Scholar, PubMed and Web of Science. Results: Genistein exhibits antioxidant properties by countering free radicals and reducing lipid peroxidation. Genistein's anti-inflammatory effects involve inhibiting proinflammatory pathways and cytokine production. Notably, it shows anticancer potential against various malignancies by promoting apoptosis, inhibiting angiogenesis, and hindering metastasis. Moreover, genistein has antidiabetic properties, enhancing insulin secretion, protecting β-cells, and improving glucose tolerance. Its antiviral and antibacterial actions contribute to inhibiting pathogen growth and viral replication. Genistein accelerates wound healing by minimizing oxidative stress, facilitating reepithelialization, and suppressing inflammation. Its potential in peptic ulcer treatment is supported by anti-inflammatory and antioxidant effects. Hepatoprotective activities include inhibiting lipid peroxidation, bolstering antioxidant defences, and modulating metabolic enzymes. Furthermore, genistein positively impacts the immune response, influencing cytokine levels, lymphocyte proliferation, and interferon production. Conclusion: Genistein's multifaceted pharmacological activities render it a promising dietary supplement with implications for diverse health conditions, warranting further comprehensive research to optimize its clinical utility.
- 1 November 2025
- Published by Bentham Science Publishers Ltd. in Current Topics in Medicinal Chemistry
- Vol. 25 (27) , 3190-3202
Therapeutic Potential of Genistein: Insights into Multifaceted Mechanisms and Perspectives for Human Wellness
Background: Genistein, a natural isoflavonoid found predominantly in legumes and soy-based foods, has garnered significant attention due to its multifaceted mechanisms and potential therapeutic applications. Chemically, genistein is a 4',5,7-Trihydroxyisoflavone having a molecular formula of C15H10O5, which enables its interactions with diverse biological targets. Objective: The main objective of this review is to summarize the pharmacological effects of genistein, elucidating its potential mechanisms of action. Furthermore, the review emphasizes genistein's impact on human health when used as a dietary supplement. Methods: The authors have gone through a vast number of article sources from various scientific databases like Google Scholar, PubMed and Web of Science. Results: Genistein exhibits antioxidant properties by countering free radicals and reducing lipid peroxidation. Genistein's anti-inflammatory effects involve inhibiting proinflammatory pathways and cytokine production. Notably, it shows anticancer potential against various malignancies by promoting apoptosis, inhibiting angiogenesis, and hindering metastasis. Moreover, genistein has antidiabetic properties, enhancing insulin secretion, protecting β-cells, and improving glucose tolerance. Its antiviral and antibacterial actions contribute to inhibiting pathogen growth and viral replication. Genistein accelerates wound healing by minimizing oxidative stress, facilitating reepithelialization, and suppressing inflammation. Its potential in peptic ulcer treatment is supported by anti-inflammatory and antioxidant effects. Hepatoprotective activities include inhibiting lipid peroxidation, bolstering antioxidant defences, and modulating metabolic enzymes. Furthermore, genistein positively impacts the immune response, influencing cytokine levels, lymphocyte proliferation, and interferon production. Conclusion: Genistein's multifaceted pharmacological activities render it a promising dietary supplement with implications for diverse health conditions, warranting further comprehensive research to optimize its clinical utility.
- 13 August 2025
- Published by Springer Nature in Current Nutrition Reports
- Vol. 14 (1) , 101
Therapeutic Potential of Citrus Species Against Metabolic Syndrome: Insights from Preclinical and Clinical Studies
Metabolic syndrome (MetSyn) is a multifactorial disorder affecting 12.5-31.4% of adults characterized by a cluster of conditions including obesity, type 2 diabetes, hypertension, cardiovascular diseases, and dyslipidemia. Lifestyle and dietary interventions are essential components of its management. With growing interest in natural sources, citrus species are one source that has been traditionally used to treat the symptoms of MetSyn. This review paper aims to provide a comprehensive summary of preclinical and clinical studies to assess the effects of citrus species and their derived phytoconstituents, such as flavonoids, limonoids, and carotenoids, on key metabolic parameters. To evaluate the therapeutic potential of citrus species in the prevention and management of metabolic syndrome based on preclinical studies using essential oils and extracts, clinical studies, and the activity of their bioactive phytoconstituents. Citrus species such as Citrus limon, Citrus medica, Citrus bergamia, Citrus aurantifolia, Citrus aurantium, Citrus grandis, Citrus maxima, Citrus sinensis, Citrus assamensis, Citrus sphaerocarpa, Citrus reticulata, Citrus japonica, and Citrus unshiu have been reported to treat metabolic syndrome. Preclinical studies demonstrate that citrus essential oils and extracts improve insulin sensitivity, reduce body weight and lipid levels, and aid in blood pressure regulation. Prominent bioactive phytoconstituents from citrus species include d-limonene, β-pinene, neral, citronellal, thymol, β-sitosterol, oleic acid, limonene, linalool, citral, α-pinene, coumarin, hexadecenoic acid, hesperidin, neohesperidin, eugenol, geraniol, and p-cymene, have also been reported to demonstrate anti-obesity, antidiabetics, antihypertensive, antidyslipidemic, and cardiovascular protective properties. Clinical trials support these findings, showing significant improvements in metabolic markers in human subjects following citrus-based interventions. Citrus species, due to their rich phytochemical composition, show considerable promise as natural therapeutic agents for mitigating the risks associated with metabolic syndrome. Further well-designed clinical trials are warranted to establish standardized dosages, to concentrate on their mechanisms of action, routes of administration, safe dosage, and potential side effects to ensure their efficacy and safety in treating MetSyn.
- 13 August 2025
- Published by Springer Nature in Current Nutrition Reports
- Vol. 14 (1) , 101
Therapeutic Potential of Citrus Species Against Metabolic Syndrome: Insights from Preclinical and Clinical Studies
Metabolic syndrome (MetSyn) is a multifactorial disorder affecting 12.5-31.4% of adults characterized by a cluster of conditions including obesity, type 2 diabetes, hypertension, cardiovascular diseases, and dyslipidemia. Lifestyle and dietary interventions are essential components of its management. With growing interest in natural sources, citrus species are one source that has been traditionally used to treat the symptoms of MetSyn. This review paper aims to provide a comprehensive summary of preclinical and clinical studies to assess the effects of citrus species and their derived phytoconstituents, such as flavonoids, limonoids, and carotenoids, on key metabolic parameters. To evaluate the therapeutic potential of citrus species in the prevention and management of metabolic syndrome based on preclinical studies using essential oils and extracts, clinical studies, and the activity of their bioactive phytoconstituents. Citrus species such as Citrus limon, Citrus medica, Citrus bergamia, Citrus aurantifolia, Citrus aurantium, Citrus grandis, Citrus maxima, Citrus sinensis, Citrus assamensis, Citrus sphaerocarpa, Citrus reticulata, Citrus japonica, and Citrus unshiu have been reported to treat metabolic syndrome. Preclinical studies demonstrate that citrus essential oils and extracts improve insulin sensitivity, reduce body weight and lipid levels, and aid in blood pressure regulation. Prominent bioactive phytoconstituents from citrus species include d-limonene, β-pinene, neral, citronellal, thymol, β-sitosterol, oleic acid, limonene, linalool, citral, α-pinene, coumarin, hexadecenoic acid, hesperidin, neohesperidin, eugenol, geraniol, and p-cymene, have also been reported to demonstrate anti-obesity, antidiabetics, antihypertensive, antidyslipidemic, and cardiovascular protective properties. Clinical trials support these findings, showing significant improvements in metabolic markers in human subjects following citrus-based interventions. Citrus species, due to their rich phytochemical composition, show considerable promise as natural therapeutic agents for mitigating the risks associated with metabolic syndrome. Further well-designed clinical trials are warranted to establish standardized dosages, to concentrate on their mechanisms of action, routes of administration, safe dosage, and potential side effects to ensure their efficacy and safety in treating MetSyn.